

Predicting the Impact of Placing Pre-event Pharmaceuticals for Anthrax

Michelle Houck
Jeffrey Herrmann

The
Institute for
Systems
Research



A. JAMES CLARK
SCHOOL OF ENGINEERING

ISR develops, applies and teaches advanced methodologies of design and analysis to solve complex, hierarchical, heterogeneous and dynamic problems of engineering technology and systems for industry and government.

ISR is a permanent institute of the University of Maryland, within the A. James Clark School of Engineering. It is a graduated National Science Foundation Engineering Research Center.

www.isr.umd.edu

Predicting the Impact of Placing Pre-event Pharmaceuticals for Anthrax

Michelle L. Houck, Jeffrey W. Herrmann
University of Maryland
College Park, MD 20742

Abstract

Finding feasible strategies to distribute antibiotics quickly to the general public in response to an anthrax attack remains a difficult challenge. Among the proposed strategies is the pre-event placement of pharmaceuticals in individual households for use only as directed by public health authorities. These medications (known as “MedKits”) would allow many exposed persons to begin treatment quickly while reducing the number who visit on points of dispensing, the primary distribution strategy. This paper describes a model that estimates the expected number of deaths in an anthrax attack by modeling the logistics of the response and the use of MedKits. The results show that increasing the number of MedKits distributed can reduce the expected number of deaths. When the population has more potential exposures, deploying MedKits is more effective. The MedKits reduce the number of potential exposures who seek prophylaxis, which allows those truly exposed (but without MedKits) to receive medication sooner, which saves lives. Beyond the scenarios considered here, the ability to predict this benefit in other scenarios will be valuable to public health officials who are considering this option.

Introduction

The deliberate release of aerosolized anthrax spores in a large city could expose many thousands of residents to this deadly disease. Promptly distributing antibiotics to those exposed is a key step in preventing illness and deaths. Avoiding delays in this distribution is critical.

Such a response will require enormous resources. State and local health departments have developed plans for points of dispensing (PODs), the primary distribution channel. These health departments realize, however, that they do not have the staff required to operate enough PODs to distribute medication to a large number of people sufficiently quickly. Therefore, other strategies have been proposed and tested (CDC, 2007). These include employing the U.S. Postal Service to deliver antibiotics directly to residences (cf. Executive Order 13527), pre-deploying pharmaceuticals to hospitals, pre-event dispensing of pharmaceuticals to first responders, and the pre-event placement of pharmaceuticals in individual households for use only as directed by public health authorities. This paper focuses on using this last option along with PODs that distribute medication from local and federal stockpiles. The pre-deployed medications are commonly known as “MedKits.”

In a 2006 study in the St. Louis, Missouri, metropolitan area, over four thousand households were given a five-day supply of antibiotics. When directed to return the medication months later, 97% of all study respondents did so; almost all (over 99%) of the MedKits were intact (CDC, 2007).

Because it is a challenge, the logistics of responding to an anthrax attack has been studied from various perspectives. Various models for predicting the performance of PODs have been developed. The BERM model (AHRQ, 2005) predicts the staffing required at a POD. Lee *et al.* (2009) describe RealOpt, a simulation and optimization tool for modeling PODs. Aaby *et al.* (2006a, b) and Herrmann (2008) describe the Clinic Planning Model Generator, a spreadsheet implementation of queueing network approximations that can quickly estimate the capacity of a POD and the wait time at each station.

Hupert *et al.* (2009) created a mathematical model that estimates the number of hospitalizations that would result from an anthrax attack and used this model to examine how the number of hospitalizations increases if medication distribution is delayed. They conclude that, in the case of a large-scale, covert aerosol anthrax release in a major city, delays in attack detection and response initiation would lead to “unsustainable levels of hospitalizations.”

The use of MedKits has been advocated by Kaplan *et al.* (2003), who describe the benefits of reducing the time needed to distribute medication. Concerns about safety and the inappropriate use of MedKits have slowed the development of this option (Troy, 2010). We are unaware, however, of any efforts to model how pre-deploying MedKits would reduce the mortality resulting from an anthrax attack. Predictions of this benefit should be valuable to public health officials who are considering this option.

The study described in this paper extends the work of Zaric *et al.* (2008), who developed a compartmental model to predict the deaths from an anthrax attack and used the model and other measures to evaluate the costs and benefits of pre-event stockpiling, distribution strategies, and rapid attack detection. Although the paper considered a broad set of questions, it focused on PODs and did not consider the impact of pre-deploying MedKits.

Holty *et al.* (2006) reviewed all of the cases of inhalational anthrax that have been published since 1900. The disease progression model used here is based upon that review.

The purpose of the work described in this paper was to develop a model that could estimate the impact of deploying MedKits in a community and to use that model to consider some possible scenarios to get some insight into the effectiveness of the MedKit strategy. To that end, we enhanced the compartmental model of Zaric *et al.* (2008). (A complete description of the model is provided in the Appendix of this paper.)

This study did not explicitly consider the cost of MedKits, as that information is quite uncertain, or other issues related to this strategy. The cost will depend greatly upon the number of MedKits that are predeployed. Other issues are still being studied. The key contribution of this study is to estimate the reduction in deaths if MedKits are predeployed. This information can be used as part of the discussion of whether to pursue this strategy.

The remainder of this paper describes the compartmental model that was used, presents the results for various scenarios (including those considered by *Zaric et al.*, 2008), and discusses the work, its limitations, and possible extensions.

Methods

Model Overview

For this study, we developed a compartmental model that includes both the progression of the disease and the logistics of treatment. A compartmental model represents the flows of individuals between compartments. Each compartment represents a number of homogeneous individuals (that is, they are identical with respect to their condition and treatment status). The compartments are mutually exclusive and collectively exhaustive; at any point in time, each individual in the population is in exactly one compartment. Compartmental models are useful when one can partition the population into distinct subsets. The models can be analyzed using differential equations (which can be solved exactly in some situations) or difference equations (which we will use here). *Jacquez (1996)* and *Walter and Contreras (1999)* provide good introductions to compartmental models with applications in biology, medicine, ecosystems, populations, and economics.

The model used here (the “MedKits model”) extends the model of *Zaric et al. (2008)* (the “POD model”) by adding additional compartments for the population that has MedKits. Like the

POD model, the MedKits model is a discrete-time model. The time period is one hour. Let $X_i(t)$ be the number of individuals in compartment i at time t , with $X(t)$ the column vector of these values. The model calculates these values for a 100-day time horizon. Let $T = 2400$ hours denote the last time period. At each point in time, we calculate the transition matrices $\phi(t)$ and $\psi(t)$, where $\phi_{ij}(t)$ is the number of individuals who move from compartment i to compartment j due to illness, recovery, or death, and $\psi_{ij}(t)$ is the number of individuals who move from compartment i to compartment j due to awareness, prophylaxis, or treatment. Let E be the 28-by-1 column vector of ones. Then, the transitions can be written as follows:

$$\begin{aligned} Y(t) &= X(t) + (\phi^T(t) - \phi(t))E \\ X(t+1) &= Y(t) + (\psi^T(t) - \psi(t))E \end{aligned}$$

or

$$\begin{aligned} Y_j(t) &= X_j(t) + \sum_{i=1}^{28} \phi_{ij}(t) - \sum_{i=1}^{28} \phi_{ji}(t) \\ X_j(t+1) &= Y_j(t) + \sum_{i=1}^{28} \psi_{ij}(t) - \sum_{i=1}^{28} \psi_{ji}(t) \end{aligned}$$

The following sections describe the features of the model, our assumptions, and the sources of data. A complete and precise mathematical description of the model is provided in the Appendix of this paper. Many of the parameters given below and used in the MedKits model are the same as those used in the POD model, but the model can be changed easily to consider scenarios with other parameters. We will exploit this in the scenario analysis described later in this paper.

Timeline

The MedKits model can be used for many scenarios. Those considered in this report are based on the following timeline. The attack occurs at $t = 0$ hours. The attack is detected at $t =$

48 hours. Local supplies of both intravenous antibiotics (IVs) for treatment and antibiotics for dispensing will become available 5 hours later at $t = 53$ hours. Intravenous antibiotics (IVs) for treatment, antibiotics for dispensing, and additional ventilators from the push pack will become available 16 or 28 hours after attack detection at $t = 64$ or 76 hours. (This is due to a 12 or 24 hour delay in receiving the push pack and another 4 hour delay in getting the material from the push pack ready.) Intravenous antibiotics (IVs) for treatment and antibiotics for dispensing from vendor-managed inventory (VMI) will become available 36 hours after attack detection at $t = 84$ hours. At $t = 96$ hours (48 hours after attack detection), complete POD capacity will be available.

Exposure

The population consists of three large subpopulations: those who were exposed to the anthrax attack (and are at risk), those who were not exposed to the anthrax attack (or inhaled too few anthrax spores to become ill), and those who believe that they may have been exposed (because of their proximity to the attack or for other reasons). The persons in this last group, called “potential exposures,” will undergo prophylaxis (by going to PODs and taking their MedKits) but cannot become ill. Let P be the total size of the population, and let N be the number exposed. Let β be the fraction of those who are not exposed but believe that they were.

Like the POD model, the MedKits model does not divide the population by age because we assume that the progression of anthrax does not depend upon age.

We assume that exposure to the attack is independent of MedKit possession. Therefore, the proportion who possess MedKits is the same in all three subpopulations. Because those who were not exposed cannot become ill and do not seek prophylaxis whether they have a MedKit or not, the model treats all of these persons in one compartment.

Those who are exposed are initially unaware of their exposure. Some become aware during incubation, some when they are prodromal, and some when they are fulminant.

Prophylaxis

Those who have MedKits do not go to PODs, so those who were exposed and potential exposures can start prophylaxis as soon as they become aware. However, some of those to whom MedKits were distributed may be unable to use them, so we assume that 5% of those given MedKits do not have them at the time of the attack.

Those who do not have MedKits will go to PODs, where the prophylaxis dispensing consists of an oral antibiotic, either ciprofloxacin or doxycycline. Prophylaxis dispensing capacity is limited. It depends upon the facilities and staff available. In the scenarios considered in this paper, we assume that there is a fixed maximum prophylaxis dispensing capacity, which is 140,000 persons per day, or 5,833.33 persons per hour. The hourly prophylaxis dispensing capacity increases in a linear manner, starting at 0 at $t = 48$ hours and reaching its maximum at $t = 96$ hours.

Prophylaxis dispensing is also limited by the availability of medication. Although a complete regimen has 60 days of medication, we assume that only 14-day abbreviated regimens are dispensed until the VMI becomes available. We assume that the local stockpile has 50,000 doses (3,571 abbreviated regimens), the push pack provides 2,718,000 doses (194,143 abbreviated regimens), and the VMI provides sufficient doses for everyone to receive a complete regimen and enough IV antibiotics for everyone who needs them.

Those who adhere to their prophylaxis will not become ill, but some who begin prophylaxis during the incubation stage will not adhere and may become ill. (We assume that those who are in the prodromal and fulminant stages will always adhere.) We considered two different adherence rates: 65% and 90%. During the 2001 anthrax attack in Washington, D.C.,

only 64% of those who received prophylaxis adhered fully to prophylaxis (Shepard *et al.*, 2002). Wein *et al.* (2003) assumed that 90% of those who receive prophylaxis will adhere.

We do not consider the duration of the regimens in the MedKits. If these regimens or those dispensed at the PODs are not complete regimens, then these persons will need to obtain the remainder. We assume that the process of dispensing the remainder will be done on a less urgent basis and will not interfere with primary dispensing capacity.

Treatment

Persons who become ill need treatment, which consists of three antibiotics (rifampin, clindamycin, and either ciprofloxacin or doxycycline) administered intravenously in an intensive care unit (ICU). All who begin treatment adhere to it.

Treatment capacity is limited by the availability of IV antibiotics, ventilators, respiratory technicians, and ICU beds. We assume that the local stockpile has 500 days of IV antibiotics, the push pack provides 21,492 days of IV antibiotics, and the VMI provides sufficient IV antibiotics for everyone who is being treated. We assume that 100 ventilators are available when the attack occurs, and the push pack provides 100 more. We assume that each respiratory technician can monitor 10 patients, 200 respiratory technicians are available when the attack occurs, and 2,000 ICU beds are available when the attack occurs. There must be at least one day's worth of IV antibiotics to begin treatment of one patient.

In this scenario, the treatment bottleneck is the lack of IV antibiotics until the local stockpile becomes available. Then the ventilators are the bottleneck, while there will be plenty of IV antibiotics for those being treated.

Disease Progression

The transition path is from the incubation stage to the prodromal stage, to the fulminant stage, and then to death.

An exposed person in the incubation stage is infected with anthrax but is asymptomatic. A person in the prodromal stage has nonheadache neurological symptoms (e.g., fever, muscle aches, fatigue) that are similar to flu. A person in the fulminant stage is severely ill, has respiratory distress, and may die within days.

We assume that only persons in the fulminant stage can die. Because it considers a short period of time, this model does not consider any other causes of death. Those in the prodromal and fulminant stages who start treatment may recover.

The rates at which persons become ill, recover, or die vary based on their status. The times to become ill, recover, or die are modeled as geometric distributions (thus, they are memoryless), and the probability of this event per time unit is the reciprocal of the mean time. The specific rates will be discussed later in the paper.

Model Compartments

Based on these preliminaries, we can now present the MedKits model, which has 28 compartments to represent distinct groups within a population. The primary distinctions between the compartments are the exposure of the individuals, the progression of the disease (including the definitive conditions of death or recovery), the treatment status, and the possession of MedKits. The model includes the 21 compartments of the POD model and adds seven more: one for death, two for potential exposures who possess MedKits, three for exposed individuals who possess MedKits, and one for those who adhere to prophylaxis (and cannot become ill). Table 1 lists all 28 compartments.

Table 1. The compartments in the MedKits model.

Compartment	Exposure, treatment status	Progression of disease	Treatment began	MedKit
1	Exposed, unaware of exposure	Incubation	n.a.	No
2	Exposed, unaware of exposure	Prodromal	n.a.	No
3	Exposed, unaware of exposure	Fulminant	n.a.	No
4	Aware of exposure	Incubation	n.a.	No
5	Aware of exposure	Prodromal	n.a.	No
6	Aware of exposure	Fulminant	n.a.	No
7	Not adhering to prophylaxis	Incubation	Prophylaxis begun in incubation stage	Both
8	In prophylaxis	Prodromal	Prophylaxis begun in incubation stage	Both
9	In prophylaxis	Prodromal	Prophylaxis begun in prodromal stage	Both
10	In prophylaxis	Fulminant	Prophylaxis begun in incubation stage	Both
11	In prophylaxis	Fulminant	Prophylaxis begun in prodromal stage	Both
12	In prophylaxis	Fulminant	Prophylaxis begun in fulminant stage	Both
13	In treatment	Prodromal	Treatment begun in prodromal stage	Both
14	In treatment	Fulminant	Prophylaxis or treatment begun in prodromal stage	Both
15	In treatment	Fulminant	Prophylaxis begun in incubation stage, treatment begun in fulminant stage	Both
16	In treatment	Fulminant	No prophylaxis or prophylaxis begun in fulminant stage	Both
17	Exposed	Recovered	n.a.	Both
18	Not exposed	n.a.	n.a.	Both
19	Potential exposure, not seeking prophylaxis	n.a.	n.a.	No
20	Potential exposure, seeking prophylaxis	n.a.	n.a.	No
21	Potential exposure, in prophylaxis	n.a.	n.a.	No
22	Exposed	Dead	n.a.	Both
23	Potential exposure, not seeking prophylaxis	n.a.	n.a.	Yes
24	Potential exposure, in prophylaxis	n.a.	n.a.	Yes
25	Exposed, unaware of exposure	Incubation	n.a.	Yes
26	Exposed, unaware of exposure	Prodromal	n.a.	Yes
27	Exposed, unaware of exposure	Fulminant	n.a.	Yes
28	Adhering to prophylaxis	Prophylaxed	Prophylaxis begun in incubation stage	Both




Figure 1. Schematic of the flows between compartments in the MedKits model.

Model Flows

In general, during each time period, a certain fraction of the individuals in a compartment will move to another compartment. This flow is governed by the values of parameters describing the disease progression (the rates at which individuals become ill, recover, or die) and the prophylaxis and treatment capacity. For a given flow, the fraction may be time-invariant (like a death rate) or may change over time as available treatment capacity ebbs and flows.

The model includes two types of flows. The first type of flow corresponds to changes in the disease in those who were exposed. The transition path is from the incubation stage to the prodromal stage, to the fulminant stage, and then to death. Those who are treated may recover. The second type of flow corresponds to changes in awareness and treatment. Exposed persons and potential exposures are first unaware of their exposure or the need for prophylaxis. When they become aware, then they seek prophylaxis (essentially, they are in a queue for prophylaxis).

Exposed persons who become sick then seek treatment and receive treatment. Figure 1 is a schematic that shows the possible flows in the MedKits model.

Because many of the compartments have multiple outflows (corresponding to different transitions), it is important to define the relative priority of the transitions. In the MedKits model, the highest priority transitions are those that correspond to the progression of the disease, recovery, and death.

The second priority transitions are those that correspond to awareness, prophylaxis, and treatment. The number who can be given prophylaxis is limited by the prophylaxis dispensing capacity, which is spread proportionally across all of the compartments with persons waiting for prophylaxis. Likewise, the number who can be treated is limited by treatment capacity, which is spread proportionally across all of the compartments with persons waiting for treatment.

Table 2 gives these probabilities, which are based on the expected times in Holty *et al.* (2006) and Zaric *et al.* (2008). For example, when the expected time to become fulminant is 122.4 hours, the probability (each hour) of becoming prodromal is $1/122.4$.

The fraction $p(t) = (F(t+1) - F(t)) / (1 - F(t))$, where $F(t)$ is the cumulative distribution function of the incubation time, which is lognormally distributed with a mean of 10.95 days, and 2.1392 and 0.713 are the mean and standard deviation of the variable's natural logarithm (Brookmeyer *et al.*, 2001). This distribution for the incubation time has been used by, among others, Wein *et al.* (2003) and Zaric *et al.* (2008).

The rate at which those who are prodromal become fulminant depends upon how long they have been ill. The parameters $\gamma = 0.0026$ and $\eta = 0.0181$ are given by Zaric *et al.* (2008). The fractions $\theta_2(t)$, $\theta_5(t)$, and $\theta_{26}(t)$ are the fraction of persons in compartments 2, 5, and 26 who have developed symptoms in the last 72 hours. Then, for $j = 2, 5, \text{ and } 26$,

$$\theta_j(t) = \min \left\{ 1, \sum_{v=1}^{72} \phi_{j-1,j}(t-v) / X_j(t) \right\}$$

Those who become ill can become aware at any time: for those who are in the prodromal stage, the probability, each hour, of becoming aware equals $1/72$; for those who are in the fulminant stage, the probability equals $1/48$. After the attack is detected (at $t = 48$ hours), for those who are in the incubation stage and for potential exposures, the probability, each hour, of becoming aware equals $1/72$. This awareness process is a special case of the Bass diffusion process.

Those who are ill and aware of their exposure (those in compartments 5 to 12) need to be treated. Those in compartments 5 and 6 are also in the queue for prophylaxis. Each hour, the capacity used to begin treating those who are waiting for treatment is determined as follows:

$$CT(t) = \min \left\{ \max \left\{ 0, \min \{ IV(t), V(t), 10 \cdot T(t), B(t) \} - \sum_{j=13}^{16} X_j(t) \right\}, \sum_{j=5}^6 Y_j(t) + \sum_{j=8}^{12} Y_j(t) \right\}$$

At time t , $IV(t)$ is the number of days of IVs remaining, $V(t)$ is the number of ventilators available, $T(t)$ is the number of technicians available, and $B(t)$ is the number of ICU beds available. Note that resources allocated to those already in treatment cannot be used to begin treating those waiting.

The persons in compartments 5, 6, and 8 to 12 all have equal priority for treatment.

Define the fraction $\pi(t)$ as follows:

$$\pi(t) = CT(t) / \left(\sum_{k=5}^6 Y_k(t) + \sum_{k=8}^{12} Y_k(t) \right).$$

Thus, the number in each of these compartments who begin treatment is $\pi(t)Y_j(t)$.

Because some of the individuals in compartments 5 and 6 will receive treatment (and don't need prophylaxis), $L_q(t)$, the total number waiting for prophylaxis, can be calculated as follows:

$$L_q(t) = Y_4(t) + Y_{20}(t) + (1 - \pi(t))(Y_5(t) + Y_6(t)).$$

The total number who receive prophylaxis at time t can be determined as follows:

$$CP(t) = \min\{I(t)/d(t), D(t), L_q(t)\}.$$

At time t , $I(t)$ is the number of days of antibiotics remaining, $d(t)$ is the number of days of antibiotics in the regimens being dispensed at that time, and $D(t)$ is the dispensing capacity (persons per hour). For $t \leq 48$, $D(t) = 0$. For $48 \leq t \leq 96$, $D(t) = \frac{t-48}{48} D_{\max}$. For $t > 96$,

$$D(t) = D_{\max}.$$

The persons in compartments 4, 5, 6, and 20 all have equal priority for prophylaxis. For each of the compartments, the number who receive prophylaxis is $CP(t)Y_4(t)/L_q(t)$,

$$CP(t)(1 - \pi(t))Y_5(t)/L_q(t), CP(t)(1 - \pi(t))Y_6(t)/L_q(t), \text{ and } CP(t)Y_{20}(t)/L_q(t).$$

Table 2. Fraction of each compartment that becomes ill, recovers, or dies each hour.

Compartment	Become prodromal	Become fulminant	Die	Recover
1	$p(t)$			
2		$\theta_2(t)\gamma + (1 - \theta_2(t))\eta$		
3			1/26.4	
4	$p(t)$			
5		$\theta_5(t)\gamma + (1 - \theta_5(t))\eta$		
6			1/26.4	
7	$p(t)$			
8		1/122.4		1/21.7
9		1/122.4		1/21.7
10			1/26.4	
11			1/26.4	
12			1/38.4	
13		1/122.4		1/21.7
14			1/24	1/720
15			1/24	1/720
16			1/38.4	1/720
25	$p(t)$			
26		$\theta_{26}(t)\gamma + (1 - \theta_{26}(t))\eta$		
27			1/26.4	

Inventory

The model also keeps track of the inventory of antibiotics available for prophylaxis and the IVs available for treatment. Each hour, the inventory of antibiotics (days of medication) is reduced by the number of days of medication dispensed (the product of the number who receive prophylaxis and the number of days in the dispensed regimen at that time). In addition, the inventory of IVs (days of IVs) is reduced by the number of those being treated (compartments 13 to 16) divided by 24.

The inventory for antibiotics and IVs increases when the local inventory becomes available (at $t = 53$ hours), when the push pack inventory is available and ready, and when the VMI becomes available (at $t = 84$ hours). The number of ventilators also increases when the push pack inventory is available and ready.

Results

To illustrate the use of the model to predict the impact of MedKits, we considered a range of scenarios like those in Zaric *et al.* (2008) and varied the number of pre-deployed MedKits. The population was 5 million people. We ran the model on several scenarios on this population varying the number of people exposed, the fraction of unexposed people who believe they were exposed (and thus use medication that could be reserved for exposed people), the time until the push pack becomes available, and the prophylaxis adherence rate. We considered attack scenarios with 50,000 exposed, 500,000 exposed and 1,250,000 exposed. Rates of 0.01, 0.1, and 0.5 were used for the fraction of the unexposed population seeking prophylaxis. Values of 12 hours and 24 hours were used for push pack availability. We used prophylaxis adherence rates of 65% and 90%. We also varied the number of MedKits distributed prior to an attack scenario. We considered increments of 500,000 MedKits from 0 to 5,000,000. Distributing zero MedKits corresponds to the scenario in Zaric *et al.* (2008), and distributing 5,000,000 MedKits corresponds to the entire population receiving MedKits.

Some expected trends were evident in our results. When all other factors were held constant and the adherence rate increased from 65% to 90%, the number of deaths decreased, and the average reduction in mortality rate was 2.6%. When the push pack availability decreased from 24 to 12 hours, the number of deaths decreased only slightly, as the average reduction in mortality rate was less than 0.5%.

In every case, the number of deaths decreased as more MedKits were distributed. In some cases this decrease was substantial while in other cases it was minimal. A key factor that affected the size of the decrease was the rate of those not exposed who believed they were (the number of potential exposures). When number of potential exposures was large, then medication

was not immediately available for those who truly needed it, which delayed their prophylaxis. In these scenarios, distributing more MedKits saved many lives. For example, in the scenario where 1,250,000 people were exposed and another 1,875,000 were potential exposures, with an adherence rate of 65% and push pack availability at 24 hours, the number of deaths decreased from 621,907 (if no MedKits had been distributed) to 140,368 (if Medkits had been distributed to the entire population). When the number of potential exposures was small, the antibiotics were going to those who needed it with minimal delays, and distributing more MedKits had minimal impact on the number of deaths. Figure 2 shows how the mortality rate decreases when more MedKits are distributed before an attack. The results in this figure for scenarios in which the prophylaxis adherence rate is 90% and the delay until additional medication becomes available is 24 hours. Note that mortality rates are highest when the number of potential exposures is large, but distributing more MedKits mitigates this phenomenon.




Figure 2. The mortality rate decreases when more MedKits are distributed before an attack. The results shown are for scenarios in which the prophylaxis adherence rate is 90% and the delay until additional medication becomes available is 24 hours. N is the number exposed. b is the fraction of non-exposed persons who will seek prophylaxis (potential exposures).

In addition, distributing MedKits can overcome problems with limited POD dispensing capacity. When POD capacity is limited, those exposed are unable to get prophylaxis in time, and the mortality rate increases. By reducing the number of person who seek prophylaxis at PODs, distributing MedKits reduces the wait time and saves lives. We considered a scenario in which 1,000,000 persons were exposed and 2,000,000 persons were potential exposures. When the maximum POD dispensing capacity was 5,000 persons per hour, the mortality rate was 53.3% when no MedKits were deployed and dropped to 11.0% when MedKits were distributed to everyone. When the maximum POD dispensing capacity was 2,500 persons per hour, the mortality rate was 72.5% when no MedKits were deployed but fell to 11.0% when MedKits were distributed to everyone. When 1,250,000 MedKits were deployed, the mortality rate fell to 53.2%. Thus, in this scenario, distributing 1,250,000 MedKits is equivalent to doubling the POD dispensing capacity.

Regardless of the number of MedKits distributed, it appears that some number of deaths is unavoidable. Even in the scenario with the smallest attack (50,000 persons exposed), the smallest number of potential exposures (1% of those not exposed, which is 49,500 in this case), a 90% adherence rate, and a 12 hour push pack availability, the estimated number of deaths was 4,102 (a mortality rate of 8.2%) even when MedKits were distributed to the entire population. The unavoidable deaths result from the delays in detecting the attack and starting prophylaxis (during which time some exposed persons become very ill), the loss of MedKits among those who received them, and the imperfect adherence rate.

Summary and Conclusions

The MedKits model can estimate the number of deaths that result from an anthrax attack when a community pre-deploys MedKits and uses PODs to dispense prophylaxis to those

without MedKits. The medication dispensed at the PODs is obtained from local and federal stockpiles and becomes available at different times after the attack is detected.

The results show that, as more MedKits are pre-deployed, the mortality rate decreases and fewer deaths occur. The reduction in mortality rate is greater when the number of potential exposures is large. Essentially, distributing MedKits counteracts the problems caused by the large number of potential exposures delaying the prophylaxis of those who were truly exposed. In addition, distributing MedKits can overcome problems with limited POD dispensing capacity.

The numerical results discussed here are for some particular scenarios. The MedKits model is capable of modeling many different scenarios by changing the parameters used in the model.

Because the MedKits model is based on the POD model, it has many of the same limitations. Both models make certain assumptions about the progression of anthrax, most particularly the assumption that the progression is not affected by age. Neither considers the impact of the disease on prophylaxis and treatment capacity.

Both models assume that becoming aware of the attack is a simple diffusion process. In real communities, however, the spread of information may be quite different, which could affect the rate at which exposed persons and potential exposures seek and begin prophylaxis.

Both models are deterministic compartmental models that estimate the expected outcome but give no insight into the distribution of possible outcomes for a given scenario. We are currently working to characterize this distribution.

While not discussed here, the MedKits model can estimate the number of persons hospitalized and the total number of patient-days.

The MedKits model assumes that those who possess MedKits have the same chance to be exposed or to be potential exposures as those who do not have MedKits. Moreover, the model assumes that the progression of anthrax in exposed persons who take the antibiotics in the MedKits is the same as in exposed persons who receive prophylaxis from a POD. The compartments and flows in the model could be modified to represent scenarios in which these assumptions and others are replaced by other conditions.

The MedKits model could be modified to evaluate the response to attacks with other noncommunicable agents such as tularemia, botulism, ricin, or yellow fever. It could be extended to consider other countermeasures strategies or to consider the dispensing of additional medication to those who receive incomplete initial regimens. Finally it could be extended to consider communicable diseases such as smallpox, but this would require considering the spread of the disease from those exposed to those who are not exposed.

The compartmental model developed here can estimate the expected number of deaths in an anthrax attack by modeling the logistics of the response and the use of MedKits. The results show that pre-deploying MedKits can reduce the expected number of deaths. Predictions of this benefit will be valuable to public health officials who are considering this option by helping them better prepare for bioterrorism attacks.

References

- Aaby, K., Herrmann, J.W., Jordan, C.S., Treadwell, M., and Wood, K., "Montgomery County's public health service uses operations research to plan emergency mass dispensing and vaccination clinics," *Interfaces*, Volume 36, Number 6, pages 569-579, 2006a.
- Aaby, K., Abbey, R.L., Herrmann, J.W., Treadwell, M., Jordan, C.S., and Wood, K., "Embracing computer modeling to address pandemic influenza in the 21st century," *Journal of Public Health Management and Practice*, Volume 12, Number 4, pages 365-372, 2006b.
- AHRQ, *Computer Staffing Model for Bioterrorism Response*. BERM Version 2.0. September 2005. Agency for Healthcare Research and Quality, Rockville, MD.
<http://www.ahrq.gov/research/biomodel.htm>

- Brookmeyer R, Blades N, Hugh-Jones M, Henderson DA, “The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak,” *Biostatistics*, Volume 2, Number 2, pages 233–47, 2001.
- Brookmeyer, R., E. Johnson, and R. Bollinger, “Public health vaccination policies for containing an anthrax outbreak,” *Nature*, Volume 432, pages 901-904, 2004.
- Centers for Disease Control and Prevention, “Emergency MedKit Evaluation Study Summary,” November 15, 2007. <http://www.bt.cdc.gov/agent/anthrax/prep/pdf/medkit-evaluation-summary-2007.pdf>.
- Executive Order 13527, “Establishing Federal Capability for the Timely Provision of Medical Countermeasures Following a Biological Attack,” December 30, 2009, published in *Federal Register*, Volume 75, Number 3, January 6, 2010.
- Herrmann, J.W., “Disseminating Emergency Preparedness Planning Models as Automatically Generated Custom Spreadsheets,” *Interfaces*, Volume 38, Number 4, pages 263-270, 2008.
- Holty, J.E., D.M. Bravata, H. Liu, R.A. Olshen, K. McDonald, and D.K. Owens, “Systematic review: a century of inhalational anthrax cases from 1900 to 2005,” *Annals of Internal Medicine*, Volume 144, Number 4, pages 270–280, 2006.
- Hupert, N., Wattson, D., Cuomo, J., Hollingsworth, E., and Neukermans, K., “Predicting hospital surge after a large-scale anthrax attack: a model-based analysis of CDC's cities readiness initiative prophylaxis recommendations,” *Medical Decision Making*, Volume 29, pages 424-437, 2009.
- Jacquez, John A., *Compartmental Analysis in Biology and Medicine*, third edition, BioMedware, Ann Arbor, Michigan, 1996.
- Kaplan, Edward H., William J. Bicknell, and Lawrence M. Wein, “How Best to Fight Against Bioterrorism,” August 5, 2003. http://www.cato.org/pub_display.php?pub_id=3189
- Lee, E.K., Chen, C.-H., Pietz, F., and Benecke, B., “Modeling and optimizing the public health infrastructure for emergency response,” *Interfaces*, Volume 39, Number 5, pages 476-490, 2009.
- Shepard, Colin W., Montse Soriano-Gabarro, Elizabeth R. Zell, James Hayslett, Susan Lukacs, Susan Goldstein, Stephanie Factor, Joshua Jones, Renee Ridzon, Ian Williams, Nancy Rosenstein, and the CDC Adverse Events Working Group, 2002, “Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence,” *Emerg Infect Dis*, Volume 8, Number 10, pages 1124–1132.
- Troy, Tevi, “Preparing for Bioterrorism,” *Weekly Standard*, February 23, 2010. http://www.hudson.org/index.cfm?fuseaction=publication_details&id=6785
- Walter, Gilbert G., and Martha Contreras, *Compartmental Modeling with Networks*, Birkhäuser, Boston, 1999.
- Wein, Lawrence M., David L. Craft, and Edward H. Kaplan, “Emergency response to an anthrax attack,” *Proc Natl Acad Sci*, Volume 100, Number 7, pages 4346–4351, 2003.
- Zaric, Gregory S., Dena M. Bravata, Jon-Erik Cleophas Holty, Kathryn M. McDonald, Douglas K. Owens and Margaret L. Brandeau, “Modeling the Logistics of Response to Anthrax Bioterrorism,” *Medical Decision Making*, Volume 28, pages 332-350, 2008.

Appendix

This appendix presents a complete and precise description of the MedKits model, including the parameter values used in the scenarios considered in this paper.

Parameters

Population size $P = 5,000,000$ persons.

Number exposed $N = 50,000$ persons (some scenarios used $N = 500,000$ and $N = 1,250,000$).

Fraction of unexposed who are potential exposures $\beta = 0.01$ (or 0.10 or 0.50).

Time when attack is detected $T_D = 48$ hours (after attack).

Time lag until PODs reach full capacity $t_{POD} = 48$ hours.

Time lag until push pack arrives $t_p = 12$ (or 24) hours.

Time lag until local inventories become available $t_L = 5$ hours.

Time lag until VMI becomes available $t_v = 36$ hours.

Time lag until push pack becomes available $t_{PR} = 4$ hours.

Number of MedKits distributed $M = 0, 500,000, \dots, P$.

Fraction of MedKits distributed that can be used when attack occurs $p_M = 0.95$.

Inventory of antibiotics available locally for PODs $I_L = 50,000$ days.

Inventory of IV antibiotics available locally $IV_L = 500$ days.

Inventory of antibiotics in push pack for PODs $I_p = 2,718,000$ days.

Inventory of IV antibiotics in push pack $IV_p = 21,492$ days.

Number of ventilators in push pack $V_p = 100$ days.

Total POD dispensing capacity $D_{\max} = 5833\frac{1}{3}$ persons per hour.

Number of days of antibiotics dispensed per regimen until VMI arrives $d_R = 14$.

Number of days of antibiotics dispensed per regimen after VMI arrives $d_v = 60$.

Prophylaxis adherence rate $\alpha = 65\%$ (or 90%).

Initialization of compartments and resources

Number in each compartment at time 0:

$$X_1(0) = (P - p_M M) \frac{N}{P}$$

$$X_{18}(0) = (1 - \beta)(P - N)$$

$$X_{19}(0) = \beta(P - p_M M) \left(1 - \frac{N}{P}\right)$$

$$X_{23}(0) = \beta p_M M \left(1 - \frac{N}{P}\right)$$

$$X_{25}(0) = p_M M \frac{N}{P}$$

$$X_j(0) = 0 \text{ for } j = 2, 3, \dots, 17, 20, 21, 22, 24, 26, 27, 28$$

POD capacity at time 0: $D(0) = 0$.

Inventory of prophylaxis antibiotics at time 0: $I(0) = 0$ days.

Inventory of IV antibiotics at time 0: $IV(0) = 0$ days.

Number of ventilators available at time 0: $V(0) = 100$.

Number of respiratory technicians at time 0: $T(0) = 200$.

Number of ICU beds at time 0: $B(0) = 2000$.

Simulation step

This step is performed for $t = 0, 1, \dots, 2399$.

Initialization of transitions

The non-zero transitions are described below.

$$\phi_{ij}(t) = 0 \text{ for } i = 1, \dots, 28 \text{ and } j = 1, \dots, 28.$$

$$\psi_{ij}(t) = 0 \text{ for } i = 1, \dots, 28 \text{ and } j = 1, \dots, 28.$$

Transitions from incubation to prodromal

$p(t) = (F(t+1) - F(t)) / (1 - F(t))$, where $F(t)$ is the cumulative distribution function of the incubation time, which is lognormally distributed with a mean of 10.95 days, and 2.1392 and 0.713 are the mean and standard deviation of the variable's natural logarithm (Brookmeyer *et al.*, 2001).

$$\phi_{i,i+1}(t) = p(t) X_i(t) \text{ for } i = 1, 4, 7, \text{ and } 25.$$

Transitions from prodromal to fulminant

$$\theta_j(t) = \min \left\{ 1, \sum_{v=1}^{72} \phi_{j-1,j}(t-v) / X_j(t) \right\} \text{ for } j = 2, 5, \text{ and } 26$$

$$\phi_{23}(t) = (0.0026 \times \theta_2 + 0.0181 \times (1 - \theta_2)) X_2(t)$$

$$\phi_{36}(t) = (0.0026 \times \theta_5 + 0.0181 \times (1 - \theta_5)) X_5(t)$$

$$\phi_{8,10}(t) = X_8(t) / 122.4$$

$$\phi_{9,11}(t) = X_9(t) / 122.4$$

$$\phi_{13,14}(t) = X_{13}(t) / 122.4$$

$$\phi_{26,27}(t) = (0.0026 \times \theta_{26} + 0.0181 \times (1 - \theta_{26})) X_{26}(t)$$

Transitions to recovery

$$\phi_{j,17}(t) = X_j(t) / 21.7 \text{ for } j = 8, 9, \text{ and } 13$$

$$\phi_{j,17}(t) = X_j(t) / 720 \text{ for } j = 14, 15, \text{ and } 16$$

Deaths

$$\phi_{j,22}(t) = X_j(t) / 26.4 \text{ for } j = 3, 6, 10, 11, \text{ and } 27$$

$$\phi_{j,22}(t) = X_j(t) / 38.4 \text{ for } j = 12 \text{ and } 16$$

$$\phi_{j,22}(t) = X_j(t) / 24 \text{ for } j = 14 \text{ and } 15$$

Determine intermediate states

$$Y_j(t) = X_j(t) + \sum_{i=1}^{28} \phi_{ij}(t) - \sum_{i=1}^{28} \phi_{ji}(t) \text{ for } j = 1, \dots, 28$$

Transitions to awareness

$$\left. \begin{aligned} \psi_{25}(t) &= (0.33 / 24) Y_2(t) \\ \psi_{36}(t) &= (0.5 / 24) Y_3(t) \\ \psi_{26,9}(t) &= (0.33 / 24) Y_{26}(t) \\ \psi_{27,12}(t) &= (0.5 / 24) Y_{27}(t) \end{aligned} \right\} \text{ for all } t \geq 0$$

$$\left. \begin{aligned} \psi_{14}(t) &= (0.33 / 24) Y_1(t) \\ \psi_{19,20}(t) &= (0.33 / 24) Y_{19}(t) \\ \psi_{23,24}(t) &= (0.33 / 24) Y_{23}(t) \\ \psi_{25,7}(t) &= (1 - \alpha)(0.33 / 24) Y_{25}(t) \\ \psi_{25,28}(t) &= \alpha(0.33 / 24) Y_{25}(t) \end{aligned} \right\} \text{ if } t \geq T_D$$

Transitions to prophylaxis and treatment

$$CT(t) = \min \left\{ \max \left\{ 0, \min \{ IV(t), V(t), 10 \cdot T(t), B(t) \} - \sum_{j=13}^{16} X_j(t) \right\}, \sum_{j=5}^6 Y_j(t) + \sum_{j=8}^{12} Y_j(t) \right\}$$

$$\pi(t) = CT(t) / \left(\sum_{k=5}^6 Y_k(t) + \sum_{k=8}^{12} Y_k(t) \right)$$

$$L_q(t) = Y_4(t) + Y_{20}(t) + (1 - \pi(t))(Y_5(t) + Y_6(t))$$

$$\text{If } t \leq T_D, D(t) = 0.$$

$$\text{If } T_D \leq t \leq T_D + t_{POD}, D(t) = \frac{t - T_D}{t_{POD}} D_{\max}.$$

$$\text{If } t > T_D + t_{POD}, D(t) = D_{\max}.$$

$$\text{If } t \leq T_D + t_V, d(t) = d_R; \text{ else } d(t) = d_V.$$

$$CP(t) = \min \{ I(t) / d(t), D(t), L_q(t) \}$$

$$\rho(t) = CP(t) / L_q(t)$$

$$\psi_{4,7}(t) = (1 - \alpha) \rho(t) Y_4(t) \quad \psi_{5,9}(t) = \rho(t) (1 - \pi(t)) Y_5(t)$$

$$\psi_{4,28}(t) = \alpha \rho(t) Y_4(t) \quad \psi_{6,12}(t) = \rho(t) (1 - \pi(t)) Y_6(t)$$

$$\psi_{20,21}(t) = \rho(t) Y_{20}(t)$$

$$\psi_{5,13}(t) = \pi(t) Y_5(t) \quad \psi_{10,15}(t) = \pi(t) Y_{10}(t)$$

$$\psi_{6,16}(t) = \pi(t) Y_6(t) \quad \psi_{11,14}(t) = \pi(t) Y_{11}(t)$$

$$\psi_{8,13}(t) = \pi(t) Y_8(t) \quad \psi_{12,16}(t) = \pi(t) Y_{12}(t)$$

$$\psi_{9,13}(t) = \pi(t) Y_9(t)$$

Update compartments

$$X_j(t+1) = Y_j(t) + \sum_{i=1}^{28} \psi_{ij}(t) - \sum_{i=1}^{28} \psi_{ji}(t)$$

Update inventory and resources

$$\left. \begin{aligned} B(t+1) &= B(t) \\ T(t+1) &= T(t) \end{aligned} \right\} \text{for all } t.$$

$$\left. \begin{aligned} I(t+1) &= I(t) - CP(t)d(t) + I_L \\ IV(t+1) &= IV(t) - \frac{1}{24} \sum_{j=13}^{16} X_j(t) + IV_L \\ V(t+1) &= V(t) \end{aligned} \right\} \text{if } t = T_D + t_L$$

$$\left. \begin{aligned} I(t+1) &= I(t) - CP(t)d(t) + I_P \\ IV(t+1) &= IV(t) - \frac{1}{24} \sum_{j=13}^{16} X_j(t) + IV_P \\ V(t+1) &= V(t) + V_P \end{aligned} \right\} \text{if } t = T_D + t_P + t_{PR}$$

$$\left. \begin{aligned} I(t+1) &= I(t) - CP(t)d(t) + d_v P \\ IV(t+1) &= IV(t) - \frac{1}{24} \sum_{j=13}^{16} X_j(t) + 3000P \\ V(t+1) &= V(t) \end{aligned} \right\} \text{if } t = T_D + t_V$$

$$\left. \begin{aligned} I(t+1) &= I(t) - CP(t)d(t) \\ IV(t+1) &= IV(t) - \frac{1}{24} \sum_{j=13}^{16} X_j(t) \\ V(t+1) &= V(t) \end{aligned} \right\} \text{otherwise}$$